التفاصيل البيبلوغرافية
| العنوان: |
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies. |
| المؤلفون: |
Lee, Elizabeth K.1 (AUTHOR) eklee@partners.org, Matulonis, Ursula A.1,2 (AUTHOR) Ursula_matulonis@dfci.harvard.edu |
| المصدر: |
Cancers. Aug2020, Vol. 12 Issue 8, p2054-2054. 1p. |
| مصطلحات موضوعية: |
*ANTINEOPLASTIC agents, *DNA, *DRUG resistance in cancer cells, *ENZYME inhibitors, *OVARIAN tumors, *BRCA genes, *DISEASE progression, *PHARMACODYNAMICS |
| الشركة/الكيان: |
UNITED States. Food & Drug Administration |
| مستخلص: |
The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, DNA damage repair, and synthetic lethality. We discuss mechanisms of resistance to PARP inhibition and how this informs on novel combinations to re-sensitize cancer cells to PARPi. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder